Online, on-demand market research connecting you to the right healthcare stakeholders.
February 12, 2019
Method: 8-minute MicroSurvey via InCrowd
Crowds: US Cardiologists, US Pulmonologists
Sample Size: n=50
Fielding Period: January 30, 2019
Screening Criteria: Qualified respondents are US-based Dermatologists who…
• Have at least five PAH patients under their care
• Are aware of products in development for the treatment of PAH
One key finding:
Most physicians feel that increased patient survival, improved health-related quality of life, and improved functional class are the most important clinical trial endpoints for new PAH treatments.
Almost half of physicians agree that the ideal mechanism of action (MOA) for new PAH drugs in development should be selective pulmonary vasodilation
Download the full report now!
We’d love to show you how physician answers are collected quickly, exceed traditional market research standards, and provide actionable insights.
Our sales team is standing by to help you customize the right program for your business.